Research programme: cancer therapeutics - KoBioLabs
Alternative Names: KBLP-005Latest Information Update: 08 Sep 2021
At a glance
- Originator CJ Cheiljedang Corp.; KoBioLabs
- Class Antineoplastics; Bacteria
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer